Mereo BioPharma announced its Q3 2026 financial results, highlighting progress in its late-stage drug programs for rare diseases, including setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency lung disease. The company is collaborating with partners Ultragenyx and Sentynl Therapeutics to advance regulatory discussions and Phase 3 trial designs, aiming to start the alvelestat Phase 3 study in early 2027. Mereo reported a net loss of $5.9 million for the quarter, with cash reserves of $26.1 million expected to fund operations into late 2027, excluding potential milestone payments. This positions Mereo for a potentially transformative 2027 as it advances its clinical pipeline and commercial strategies.
Mereo BioPharma's Q3 2026 financial results provide context for readers interested in biotech developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health stocks, 121 rose and 18 fell. Notable movers include IONS at USD 31.20 with a -20.85% change, IBRX at USD 7.49 down 13.26%, and ABEO at USD 3.65 down 12.47%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
